JEAN PELLEGALLE: Open Payments
NPI 1013528884 · LONGVIEW, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,329 in 120 payments from 11 companies in 2025. Trend: 2023 $33 · 2024 $1,497 · 2025 $2,329
Food & beverage: $2,329
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 29 | $679 |
| Vanda Pharmaceuticals Inc. | 22 | $505 |
| Teva Pharmaceuticals USA, Inc. | 14 | $315 |
| ABBVIE INC. | 16 | $227 |
| Alkermes, Inc. | 13 | $139 |
| Lundbeck LLC | 10 | $136 |
| Luye Pharma (USA) Ltd. | 5 | $109 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $102 |
| Otsuka America Pharmaceutical, Inc. | 4 | $86 |
| Janssen Pharmaceuticals, Inc | 1 | $18 |
Products named: INGREZZA, FANAPT, VRAYLAR, REXULTI, AUSTEDO XR, ARISTADA, UZEDY, ERZOFRI EXTENDED-RELEASE.
Industry payments across TX — which companies pay providers there.
